Julien Zuber

List of Publications by Year
in descending order

57 papers	3,700 citations	201674 27 h-index	144013 57 g-index
61 all docs	61 docs citations	61 times ranked	4353 citing authors

#	Article	IF	Citations
1	Genetics and Outcome of Atypical Hemolytic Uremic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 554-562.	4.5	567
2	Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nature Reviews Nephrology, 2012, 8, 643-657.	9.6	448
3	Haemolytic uraemic syndrome. Lancet, The, 2017, 390, 681-696.	13.7	397
4	Tracking donor-reactive T cells: Evidence for clonal deletion in tolerant kidney transplant patients. Science Translational Medicine, 2015, 7, 272ra10.	12.4	191
5	New insights into postrenal transplant hemolytic uremic syndrome. Nature Reviews Nephrology, 2011, 7, 23-35.	9.6	169
6	Combined Posttransplant Prophylactic IVIg/Anti-CD 20/Plasmapheresis in Kidney Recipients With Preformed Donor-Specific Antibodies: A Pilot Study. Transplantation, 2010, 89, 1403-1410.	1.0	133
7	Impact of Norovirus/Sapovirus-Related Diarrhea in Renal Transplant Recipients Hospitalized for Diarrhea. Transplantation, 2011, 92, 61-69.	1.0	130
8	Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept. Transplantation, 2021, 105, e94-e95.	1.0	105
9	Bidirectional intragraft alloreactivity drives the repopulation of human intestinal allografts and correlates with clinical outcome. Science Immunology, 2016, 1, .	11.9	98
10	Donor-Specific Antibodies Accelerate Arteriosclerosis after Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2011, 22, 975-983.	6.1	88
11	Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept. American Journal of Transplantation, 2021, 21, 4043-4051.	4.7	84
12	Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2019, 30, 2449-2463.	6.1	81
13	Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplantation Reviews, 2013, 27, 117-125.	2.9	74
14	Quantifying size and diversity of the human T cell alloresponse. JCI Insight, 2018, 3, .	5.0	69
15	COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities. American Journal of Transplantation, 2021, 21, 1285-1294.	4.7	69
16	Mechanisms of Mixed Chimerism-Based Transplant Tolerance. Trends in Immunology, 2017, 38, 829-843.	6.8	66
17	Long-term Outcomes of Kidney Transplantation in Patients With High Levels of Preformed DSA. Transplantation, 2017, 101, 2440-2448.	1.0	60
18	Diarrhea After Kidney Transplantation. Transplantation, 2014, 98, 806-816.	1.0	55

#	Article	IF	Citations
19	Early expansion of donor-specific Tregs in tolerant kidney transplant recipients. JCI Insight, 2018, 3, .	5.0	54
20	Cryptosporidium spp. Infection in Solid Organ Transplantation. Transplantation, 2017, 101, 826-830.	1.0	44
21	Human Intestinal Allografts Contain Functional Hematopoietic Stem and Progenitor Cells that Are Maintained by a Circulating Pool. Cell Stem Cell, 2019, 24, 227-239.e8.	11.1	43
22	Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome. Haematologica, 2019, 104, 2501-2511.	3.5	40
23	Eculizumab in renal transplantation. Transplantation Reviews, 2013, 27, 90-92.	2.9	39
24	Single-cell analysis of FOXP3 deficiencies in humans and mice unmasks intrinsic and extrinsic CD4+ T cell perturbations. Nature Immunology, 2021, 22, 607-619.	14.5	35
25	Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction. Nature Communications, 2021, 12, 6446.	12.8	35
26	Long-term outcome of third kidney transplants. Nephrology Dialysis Transplantation, 2007, 22, 2693-2700.	0.7	34
27	Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder. Journal of Hepatology, 2017, 67, 1334-1339.	3.7	32
28	Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept. American Journal of Transplantation, 2021, 21, 2448-2458.	4.7	31
29	Lymphohematopoietic graft-versus-host responses promote mixed chimerism in patients receiving intestinal transplantation. Journal of Clinical Investigation, 2021, 131, .	8.2	31
30	Decline and loss of antiâ€“SARS-CoV-2 antibodies in kidney transplant recipients inÂthe 6 months following SARS-CoV-2 infection. Kidney International, 2021, 99, 486-488.	5.2	30
31	De Novo Donor-Specific Human Leukocyte Antigen Antibodies in Nonsensitized Kidney Transplant Recipients After T Cell-Mediated Rejection. Transplantation, 2015, 99, 965-972.	1.0	28
32	Severe FOXP3+ and NaÃ¯ve T Lymphopenia in a Non-IPEX Form of Autoimmune Enteropathy Combined With an Immunodeficiency. Gastroenterology, 2007, 132, 1694-1704.	1.3	26
33	Clinical and immunological features of very long-term survivors with a single renal transplant. Transplant International, 2012, 25, 545-554.	1.6	26
34	Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection. Kidney International, 2022, 101, 1290-1293.	5.2	25
35	Long-term CD4 lymphopenia is associated with accelerated decline of kidney allograft function. Nephrology Dialysis Transplantation, 2016, 31, 487-495.	0.7	23
36	Glomerular Collapse Associated With Subtotal Renal Infarction in Kidney Transplant Recipients With Multiple Renal Arteries. American Journal of Kidney Diseases, 2010, 55, 558-565.	1.9	22

#	Article	IF	Citations
37	Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence. Transplantation, 2017, 101, 2924-2930.	1.0	21
38	Immune Checkpoint Inhibitors in Transplantationâ€"A Case Series and Comprehensive Review of Current Knowledge. Transplantation, 2021, 105, 67-78.	1.0	21
39	Prognostic significance of graft Foxp3 expression in renal transplant recipients: a critical review and atempt to reconcile discrepancies. Nephrology Dialysis Transplantation, 2013, 28, 1100-1111.	0.7	20
40	HNF1B-related diabetes triggered by renal transplantation. Nature Reviews Nephrology, 2009, 5, 480-484.	9.6	18
41	Efficacy and Safety of Direct Oral Anticoagulants in Kidney Transplantation: A Single-center Pilot Experience. Transplantation, 2020, 104, 2625-2631.	1.0	15
42	High-Dosage Intravenous Immunoglobulinâ€"Associated Macrovacuoles Are Associated with Chronic Tubulointerstitial Lesion Worsening in Renal Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1461-1468.	4.5	14
43	Severe relapse of SARS-CoV-2 infection in a kidney transplant recipient with negative nasopharyngeal SARS-CoV-2 RT-PCR after rituximab. American Journal of Transplantation, 2022, 22, 2099-2103.	4.7	14
44	Chronic histiocytic intervillositis: manifestation of placental alloantibody-mediated rejection. American Journal of Obstetrics and Gynecology, 2021, 225, 662.e1-662.e11.	1.3	13
45	Donor-targeted serotherapy as a rescue therapy for steroid-resistant acute GVHD after HLA-mismatched kidney transplantation. American Journal of Transplantation, 2020, 20, 2243-2253.	4.7	11
46	Harnessing regulatory T cells for transplant tolerance in the clinic through mTOR inhibition. Current Opinion in Organ Transplantation, 2011, 16, 606-613.	1.6	10
47	A combination of cyclophosphamide and interleukin-2 allows CD4+ T cells converted to Tregs to control scurfy syndrome. Blood, 2021, 137, 2326-2336.	1.4	9
48	No clinical benefit of rapid versus gradual tapering of immunosuppression to treat sustained <scp>BK</scp> virus viremia after kidney transplantation: a singleâ€center experience. Transplant International, 2019, 32, 481-492.	1.6	8
49	Time-dependent lymphocyte count after transplantation is associated with higher risk of graft failure and death. Kidney International, 2021, 99, 1189-1201.	5.2	8
50	CRISPR/Cas9-Engineered HLA-Deleted Glomerular Endothelial Cells as a Tool to Predict Pathogenic Non-HLA Antibodies in Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2021, 32, 3231-3251.	6.1	8
51	Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus. Transplant Infectious Disease, 2018, 20, e12846.	1.7	7
52	A DL-4- and TNFÎ±-based culture system to generate high numbers of nonmodified or genetically modified immunotherapeutic human T-lymphoid progenitors. Cellular and Molecular Immunology, 2021, 18, 1662-1676.	10.5	6
53	Ravulizumab for the Treatment of aHUS in Adults: Improving Quality of Life. Kidney International Reports, 2021, 6, 1489-1491.	0.8	5
54	Ig-responsive relapsing inflammatory syndrome following COVID-19 in a kidney transplant recipient. Kidney International, 2021, 99, 767-768.	5.2	3

#	Article	IF	Citations
55	Baseline graft status is a critical predictor of kidney graft failure after diarrhoea. Nephrology Dialysis Transplantation, 2019, 34, 1597-1604.	0.7	2
56	The Case | Cardiac tamponade in a kidney transplant recipient with chronic inflammation. Kidney International, 2021, 100, 487-488.	5.2	0
57	Editorial: Immunogenomics of Solid Organ and Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2022, 13, 878314.	4.8	0